Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03419702
Other study ID # METC173015
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 10, 2018
Est. completion date December 3, 2021

Study information

Verified date March 2022
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the proposed study is to examine and understand the impact of long-term almond consumption on chronic glucose metabolism in subjects with impaired glucose tolerance and/or impaired fasting glucose.


Description:

Objectives: Secondary objectives are to investigate if improved chronic glucose metabolism in subjects with impaired glucose tolerance and/or impaired fasting glucose after long-term almond consumption translates into improved peripheral and brain vascular function, and enhanced cognitive performance. In addition, the investigators will address to what extent improved chronic glucose metabolism in subjects with impaired glucose tolerance and/or impaired fasting glucose after long-term almond consumption can be explained by (combined) effects of lowered hepatic lipid accumulation and inflammation, skeletal muscle characteristics, visceral and subcutaneous fat accumulation, pancreatic function or fecal microbiota composition. Study design: The proposed study will be a 12 months randomised, controlled trial with a cross-over design. Two experimental periods of five months will be separated by a two months washout period. Study population: Forty-three impaired glucose tolerant and/or impaired fasting glucose subjects, with overweight and mild obesity (BMI 25-35 kg/m2), aged 40-70 years. Intervention: During the intervention period of 5 months, subjects will receive daily 50 gr almonds, but not in the 2 months washout and 5 months control periods.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date December 3, 2021
Est. primary completion date December 3, 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Aged between 40-70 years - Men and women - BMI between 25-35 kg/m2 (overweight and obese) - Being classified as having impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG). IGT is defined according the criteria of the WHO and American Diabetes Association (ADA) as two-hour glucose concentrations of 7.8 to 11.0 mmol/l (140 to 199 mg per dL) during the 75-g oral glucose tolerance test. IFG is defined as having a fasting plasma glucose between 6.1 and 7.0 mmol/l (110 to 125 mg per dL) and a two-hour glucose concentration below 7.8 mmol/l (140 mg per dL). - Serum total cholesterol < 8.0 mmol/L (further testing is recommended for excessive hyperlipidemia [serum total cholesterol = 8.0 mmol/L] according to the Standard for cardiovascular risk management of the Dutch general practitioners community [NHG]) - Serum triacylglycerol < 4.52 mmol/L - No current smoker - No diabetic patients - No familial hypercholesterolemia - No abuse of drugs - Not more than 4 alcoholic consumption per day with a maximum of 21 per week - Stable body weight (weight gain or loss < 3 kg in the past three months) - No use of medication known to treat blood pressure, lipid or glucose metabolism - No use of an investigational product within another biomedical intervention trial within the previous 1-month - No severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis - No active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident - Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study - No difficult venipuncture as evidenced during the screening visit - Willing to comply to study protocol during study - Informed consent signed Exclusion Criteria: - Allergy or intolerance to almonds - Serum total cholesterol = 8.0 mmol/L - Serum triacylglycerol = 4.52 mmol/L - Current smoker, or smoking cessation <12 months - Diabetic patients - Familial hypercholesterolemia - Abuse of drugs - More than 4 alcoholic consumptions per day or 21 per week - Unstable body weight (weight gain or loss > 3 kg in the past three months) - Use medication known to treat blood pressure, lipid or glucose metabolism - Use of an investigational product within another biomedical intervention trial within the previous 1-month - Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis - Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident - Not willing to give up being a blood donor from 8 weeks before the start of the study, during the study or for 4 weeks after completion of the study - Not or difficult to venipuncture as evidenced during the screening visit - Use of over-the-counter and prescribed medication or supplements, which may interfere with study measurements to be judged by the principal investigator; - Use of oral antibiotics in 40 days or less prior to the start of the study; - Blood donation in the past 3 months before the start of the study - Not willing to comply to study protocol during study or sign informed consent

Study Design


Intervention

Dietary Supplement:
Almonds
During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.

Locations

Country Name City State
Netherlands Maastricht University, Department of Nutrition and Movement Sciences Maastricht Limburg

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Medical Center Almond Board of California

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Insulin sensitivity Glucose infusion rate during a hyper-insulinemic euglycemic clamp. Change from control period (week 22 and week 52)
Secondary Glucose concentrations Fasting plasma glucose concentrations will be determined in blood samples. Glucose will be measured at week 0, week 5, week 10, week 21, week 22, week 30, week 35, week 40, week 51, week 52
Secondary Markers for fasting lipid metabolism Markers for fasting lipid metabolism include serum total cholesterol (mmol/L), HDL cholesterol (mmol/L), and triacylglycerol (mmol/L) concentrations. These markers will be measured at week 0, week 5, week 10, week 21, week 22, week 30, week 35, week 40, week 51, week 52
Secondary LDL cholesterol concentrations Fasting LDL cholesterol concentrations will be determined in blood samples using the Friedewald equation. These markers will be calculated from measurements at week 0, week 5, week 10, week 21, week 22, week 30, week 35, week 40, week 51, week 52
Secondary C-reactive protein concentrations Concentrations of CRP will be determined in blood samples. CRP will be measured at week 0, week 5, week 10, week 21, week 22, week 30, week 35, week 40, week 51, week 52
Secondary Blood pressure Systolic and diastolic blood pressure. Blood pressure will be measured at week 0, week 5, week 10, week 21, week 22, week 30, week 35, week 40, week 51, week 52
Secondary Body weight Body weight in kg. Body weight will be measured at week 0, week 5, week 10, week 21, week 22, week 30, week 35, week 40, week 51, week 52
Secondary Body circumferences Waist and hip circumferences. Waist and hip circumferences will be measured at week 0, week 5, week 10, week 21, week 22, week 30, week 35, week 40, week 51, week 52
Secondary Pulse Wave Analysis Vascular function (arterial stiffness). Change from control period (week 21 and week 51)
Secondary Pulse Wave Velocity Vascular function (arterial stiffness). Change from control period (week 21 and week 51)
Secondary Retinal microvascular caliber Arteriovenous ratio and diameter of retinal arterioles and venules will be measured by retinal microvascular imaging. Change from control period (week 21 and week 51)
Secondary Cognitive performance Cambridge Neuropsychological Test Automated Battery. Cognition will be tested at week 0, week 10, week 21, week 30, week 40, week 51.
Secondary Markers for low-grade systemic inflammation Markers for low-grade systemic inflammation include IL-6, IL-8, TNF-alpha and SAA. Change from control period (week 21 and week 51)
Secondary Markers for endothelial dysfunction Markers for endothelial dysfunction include sVCAM-1, sICAM-1 and soluble E-selectin. Change from control period (week 21 and week 51)
Secondary Markers for postprandial lipid metabolism Markers for postprandial lipid metabolism include triacylglycerol (mmol/L) and NEFA concentrations. Change from control period (week 21 and week 51)
Secondary Markers for fasting and postprandial glucose and insulin metabolism Markers for fasting and postprandial glucose and insulin metabolism include plasma glucose, serum insulin, C-peptide and HbA1c concentrations. Also HOMA-IR will be calculated. Change from control period (week 21 and week 51)
Secondary Markers for liver function Markers for liver function include ALAT and ASAT concentrations. Change from control period (week 21 and week 51)
Secondary Markers for nerve growth Markers for nerve growth include BDNF concentrations. Change from control period (week 21 and week 51)
Secondary Markers for advanced glycation endproducts Markers for advanced glycation endproducts include dicarbonyl, CML, CEL and MG-H1 concentrations. Change from control period (week 21 and week 51)
Secondary Nitric oxides concentrations Concentrations of NOx will be determined in blood samples. Change from control period (week 21 and week 51)
Secondary Cerebral blood flow Arterial Spin labeling will be performed to determine cerebral blood flow. Change from control period (week 22 and week 52)
Secondary Fat distribution in abdomen Magnetic Resonance Imaging measurements will be included to quantify abdominal fat compartments (i.e. subcutaneous and visceral fat) and fat content of abdominal organs (i.e. liver and pancreas). Change from control period (week 22 and week 52)
Secondary Biopsies adipose tissue Fat biopsies to examine fat cell size and inflammation in adipose tissue. Change from control period (week 22 and week 52)
Secondary Biopsies muscle tissue Muscle biopsies to examine mitochondrial function. Change from control period (week 22 and week 52)
Secondary Lipid oxidation Energy expenditure and substrate metabolism will be calculated from measurements via indirect calorimetry during the postprandial test. Indirect calorimetry will be performed at week 21, week 22, week 51, week 52 at several time slots.
Secondary Glucose oxidation Energy expenditure and substrate metabolism will be calculated from measurements via indirect calorimetry during the postprandial test. Indirect calorimetry will be performed at week 21, week 22, week 51, week 52 at several time slots.
Secondary Blood pressure profiles Blood pressure profiles will be measured for 48 hr via a Mobil-O-Graph. Change from control period (week 21 and week 51)
Secondary Glucose profiles Glucose profiles will be measured for 48 hr using the FreeStyle Libre Pro. Change from control period (week 21 and week 51)
Secondary Physical activity profiles Physical activity patterns will be monitored for 48 hr with the MOX device. Change from control period (week 21 and week 51)
Secondary Microbiota composition Fecal samples to be used for analysing microbiota composition will be collected. Change from control period (week 21 and week 51)
Secondary General well-being Quality of life and Affect grid questionnaires will be assessed. General well-being will be tested at week 0, week 10, week 21, week 30, week 40, week 51.
Secondary Food frequency Food frequency questionnaire will be assessed. Food frequency will be tested at week 0, week 10, week 21, week 30, week 40, week 51.
Secondary Skinfold measurements Calliper testing for determining body fat composition. Change from control period (week 22 and week 52)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Completed NCT04611477 - Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals N/A
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A